FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed invention relates to such compositions and pharmaceutical compositions, which include poxviruses, and namely to those, which include extracellular enveloped viruses. Claimed invention also relates to such method, which is intended for production of poxviruses, as well as poxviruses, obtained in accordance with claimed invention. In addition, claimed invention also relates to application of claimed poxviruses and said composition for medication preparation.
EFFECT: obtaining pharmaceutical compositions, which include poxviruses.
11 cl, 3 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PRODUCTION OF POX VIRUSES AND COMPOSITION OF POX VIRUSES | 2013 |
|
RU2581910C2 |
| METHOD TO PRODUCE POX VIRUSES AND COMPOSITIONS OF POX VIRUSES | 2007 |
|
RU2489486C2 |
| M2-DEFECTIVE POXVIRUS | 2019 |
|
RU2819245C2 |
| PERSONALIZED VACCINE | 2018 |
|
RU2779987C2 |
| COMPOSITIONS AND METHODS FOR INCREASING THE STABILITY OF TRANSGENES IN POXVIRUSES | 2017 |
|
RU2756534C2 |
| POX VIRAL ONCOLYTIC VECTORS | 2008 |
|
RU2557312C2 |
| POXVIRAL ONCOLYTIC VECTORS | 2008 |
|
RU2508401C2 |
| POXVIRAL ONCOLYTIC VECTORS | 2008 |
|
RU2503717C2 |
| COMBINATION THERAPY FOR TREATING CANCER WITH POXVIRUS EXPRESSING TUMOUR ANTIGEN AND ANTAGONIST AND/OR AGONIST OF IMMUNE CHECKPOINT INHIBITOR | 2014 |
|
RU2714142C2 |
| COMBINATION OF POXVIRUS ENCODING HUMAN PAPILLOMA VIRUS POLYPEPTIDES, AND IL-2 WITH ANTI-PD-L1 ANTIBODY | 2020 |
|
RU2824962C1 |
